STOKE ASO 3
Alternative Names: STOKEASO-3Latest Information Update: 31 Mar 2025
At a glance
- Originator Stoke Therapeutics
- Developer ACADIA Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 26 Feb 2025 Early research in Unspecified in USA (unspecified route) before February 2025 (Acadia Pharmaceuticals pipeline, February 2025)